{"id":19150,"date":"2025-10-24T15:30:09","date_gmt":"2025-10-24T08:30:09","guid":{"rendered":"https:\/\/nhathuocngocanh.com\/bp\/?p=19150"},"modified":"2025-10-24T15:30:09","modified_gmt":"2025-10-24T08:30:09","slug":"nadolol-oral-suspension","status":"publish","type":"post","link":"https:\/\/nhathuocngocanh.com\/bp\/nadolol-oral-suspension\/","title":{"rendered":"Nadolol Oral Suspension"},"content":{"rendered":"

Edition: BP 2025 (Ph. Eur. 11.6 update)<\/p>\n

Action and use<\/strong><\/p>\n

Beta-adrenoceptor antagonist.<\/p>\n

DEFINITION<\/h2>\n
Nadolol Oral Suspension is a suspension of Nadolol in a suitable vehicle.<\/p>\n
The oral suspension complies with the requirements stated under Oral Liquids and with the following requirements. Where appropriate, the oral suspension also complies with the requirements stated under Unlicensed Medicines.<\/em><\/p>\n
Content of nadolol, C_{17<\/sub>H_{27<\/sub>NO_{4<\/sub><\/strong><\/p>\n}}}
95.0 to 105.0% of the stated amount.<\/p>\n
IDENTIFICATION<\/h2>\n
A. Carry out the method for thin-layer chromatography, Appendix III A, using the following solutions in 0.1M hydrochloric acid.<\/p>\n
(1) Dilute a quantity of the oral suspension containing 10 mg of Nadolol to 10 mL, centrifuge at 3500 rpm for 25 minutes and filter the supernatant liquid through a 0.45-\u00b5m nylon filter.<\/p>\n
(2) 0.1% w\/v of nadolol BPCRS.<\/p>\n
(3) Equal volumes of solutions (1) and (2).<\/p>\n
CHROMATOGRAPHIC CONDITIONS<\/h3>\n
(a) Use a silica gel precoated plate (Merck silica gel 60 F254 plates are suitable).<\/p>\n
(b) Use the mobile phase as described below.<\/p>\n
(c) Apply 25 \u00b5L of each solution.<\/p>\n
(d) Develop the plate to 10 cm.<\/p>\n
(e) After removal of the plate, dry in air and examine under ultraviolet light (254 nm).<\/p>\n
MOBILE PHASE<\/h3>\n
1 volume of 2M ammonium hydroxide, 1 volume of dichloromethane and 8 volumes of acetone.<\/p>\n
SYSTEM SUITABILITY<\/h3>\n
The test is not valid unless the chromatogram obtained with solution (3) appears as a single compact spot.<\/p>\n
CONFIRMATION<\/h3>\n
The principal spot in the chromatogram obtained with solution (1) corresponds to that in the chromatogram obtained with solution (2).<\/p>\n
B. In the Assay, the retention time of the principal peak in the chromatogram obtained with solution (1) is similar to that of the principal peak in the chromatogram obtained with solution (2).<\/p>\n
TESTS<\/h2>\n
Dissolution<\/h3>\n
Complies with the requirements stated under Unlicensed Medicines, Oral Suspensions. Use a volume of the oral suspension containing one dose.<\/p>\n
Related substances<\/h3>\n
Carry out the method for liquid chromatography, Appendix III D, using the following solutions prepared immediately before use in a mixture of 1 volume of acetonitrile R1 and 3 volumes of water.<\/p>\n
(1) Disperse a quantity of the oral suspension containing 20 mg of Nadolol in 10 mL and shake for 10 minutes; dilute to contain 0.1% w\/v of Nadolol and filter through a 0.45-\u00b5m nylon filter.<\/p>\n
(2) Dilute 1 volume of solution (1) to 50 volumes and further dilute 1 volume to 20 volumes.<\/p>\n
(3) Dissolve the contents of a vial of nadolol impurity mixture EPCRS in 1 mL of solution (2).<\/p>\n
CHROMATOGRAPHIC CONDITIONS<\/h4>\n
(a) Use a stainless steel column (25 cm \u00d7 4.0 mm) packed with end-capped octadecylsilyl silica gel for chromatography (5 \u00b5m) (Lichrospher 100 RP 18 is suitable).<\/p>\n
(b) Use gradient elution and the mobile phase described below.<\/p>\n
(c) Use a flow rate of 1 mL per minute.<\/p>\n
(d) Use a column temperature of 40\u00b0.<\/p>\n
(e) Use a detection wavelength of 206 nm.<\/p>\n
(f) Inject 20 \u00b5L of each solution.<\/p>\n
MOBILE PHASE<\/h4>\n
Mobile phase A<\/em> 0.56% w\/v of sodium octanesulfonate, adjusted to pH 3.5 with a 30% w\/v solution of orthophosphoric acid.<\/p>\n
Mobile phase B<\/em>\u00a0 acetonitrile R1.<\/p>\n\n\n\n\n\n\n\n\n\n
Time (Minutes)<\/strong><\/td>\n Mobile phase A (% v\/v)<\/strong><\/td>\n Mobile phase B (% v\/v)<\/strong><\/td>\n Comment<\/strong><\/td>\n<\/tr>\n
0-7<\/td>\n 84<\/td>\n 16<\/td>\n isocratic<\/td>\n<\/tr>\n
7-30<\/td>\n 84\u219272<\/td>\n 16\u219228<\/td>\n linear gradient<\/td>\n<\/tr>\n
30-35<\/td>\n 72\u219262<\/td>\n 28\u219238<\/td>\n linear gradient<\/td>\n<\/tr>\n
35-55<\/td>\n 62<\/td>\n 38<\/td>\n isocratic<\/td>\n<\/tr>\n
55-56<\/td>\n 62\u219284<\/td>\n 38\u219216<\/td>\n linear gradient<\/td>\n<\/tr>\n
56-60<\/td>\n 84<\/td>\n 16<\/td>\n re-equilibration<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
When the chromatograms are recorded under the prescribed conditions the retention time of nadolol is about 30 minutes and the relative retentions with respect to nadolol are: impurity A, about 0.14; impurity C (doublet), about 0.71 and 0.77; impurity D, about 1.2.<\/p>\n
Use the chromatogram supplied with nadolol impurity mixture EPCRS and the chromatogram obtained with solution (3) to identify the peaks due to impurities A and D.<\/p>\n
SYSTEM SUITABILITY<\/h4>\n
The test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks due to nadolol and impurity D is at least 8.0.<\/p>\n
LIMITS<\/h4>\n
Identify any peaks in the chromatogram obtained with solution (1) corresponding to impurity C (doublet) and multiply the sum of the areas of the two peaks by the following correction factor: 0.7.<\/p>\n
In the chromatogram obtained with solution (1):<\/p>\n
the area of any peak corresponding to impurity A, C or D is not greater than twice the area of the principal peak in the chromatogram obtained with solution (2) (0.2% of each);<\/p>\n
the area of any other secondary peak is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (0.1%);<\/p>\n
the sum of the areas of all the secondary peaks is not greater than five times the area of the principal peak in the chromatogram obtained with solution (2) (0.5%).<\/p>\n
Disregard any peak with an area less than half the area of the principal peak in the chromatogram obtained with solution (2) (0.05%).<\/p>\n
ASSAY<\/h2>\n
Carry out the method for liquid chromatography, Appendix III D, using the following solutions.<\/p>\n
(1) Disperse a weighed quantity of the oral suspension containing 20 mg of Nadolol in 75 mL of mobile phase A and shake for 15 minutes. Add sufficient mobile phase A to produce 100 mL and filter through a 0.45-\u00b5m nylon filter.<\/p>\n
(2) 0.02% w\/v of nadolol BPCRS in mobile phase A.<\/p>\n
CHROMATOGRAPHIC CONDITIONS<\/h3>\n
(a) Use a stainless steel column (25 cm \u00d7 4.6 mm) packed with spherical particles of silica the surface of which has been modified with chemically bonded dimethylsilyl groups (7 \u00b5m) (Nucleosil C2 is suitable).<\/p>\n
(b) Use gradient elution and the mobile phase described below.<\/p>\n
(c) Use a flow rate of 1 mL per minute.<\/p>\n
(d) Use an ambient column temperature.<\/p>\n
(e) Use a detection wavelength of 220 nm.<\/p>\n
(f) Inject 20 \u00b5L of each solution.<\/p>\n
MOBILE PHASE<\/h3>\n
Mobile phase A<\/em>\u00a0 25 volumes of methanol and 75 volumes of mobile phase B.<\/p>\n
Mobile phase B<\/em>\u00a0 Dissolve 23.36 g of sodium chloride in 5200 mL of water, add 4 mL of 0.1M hydrochloric acid and mix.<\/p>\n
Mobile phase C<\/em>\u00a0 methanol.<\/p>\n\n\n\n\n\n\n\n\n
Time (Minutes)<\/strong><\/td>\n Mobile phase A (% v\/v)<\/strong><\/td>\n Mobile phase B (% v\/v)<\/strong><\/td>\n Mobile phase C (% v\/v)<\/strong><\/td>\n Comment<\/strong><\/td>\n<\/tr>\n
0-15<\/td>\n 100<\/td>\n 0<\/td>\n 0<\/td>\n isocratic<\/td>\n<\/tr>\n
15-16<\/td>\n 100\u21920<\/td>\n 0\u219250<\/td>\n 0\u219250<\/td>\n linear gradient<\/td>\n<\/tr>\n
16-25<\/td>\n 0<\/td>\n 50<\/td>\n 50<\/td>\n isocratic wash step<\/td>\n<\/tr>\n
25-26<\/td>\n 0\u2192100<\/td>\n 0<\/td>\n 0<\/td>\n linear gradient<\/td>\n<\/tr>\n
26-35<\/td>\n 100<\/td>\n 0<\/td>\n 0<\/td>\n re-equilibration<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
DETERMINATION OF CONTENT<\/h3>\n
Determine the weight per mL of the oral suspension, Appendix V G, and calculate the content of C_{17<\/sub>H_{27<\/sub>NO_{4<\/sub>, weight in volume, using the declared content of C_{17<\/sub>H_{27<\/sub>NO_{4<\/sub> in nadolol BPCRS.<\/p>\n}}}}}}
IMPURITIES<\/h2>\n
The impurities limited by the requirements of this monograph include impurities A, C and D listed under Nadolol.<\/p>\n","protected":false},"excerpt":{"rendered":"
Edition: BP 2025 (Ph. Eur. 11.6 update) Action and use Beta-adrenoceptor antagonist. DEFINITION Nadolol Oral Suspension is a suspension of Nadolol in a suitable vehicle. The oral suspension complies with the requirements stated under Oral Liquids and with the following requirements. Where appropriate, the oral suspension also complies with the requirements stated under Unlicensed Medicines….<\/p>\n","protected":false},"author":5,"featured_media":19151,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[175],"tags":[],"class_list":["post-19150","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-formulated-preparations-specific-monographs"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/19150","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=19150"}],"version-history":[{"count":2,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/19150\/revisions"}],"predecessor-version":[{"id":19156,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/19150\/revisions\/19156"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/19151"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=19150"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=19150"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=19150"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

MOBILE PHASE<\/h3>\n1 volume of 2M ammonium hydroxide, 1 volume of dichloromethane and 8 volumes of acetone.<\/p>\n

SYSTEM SUITABILITY<\/h3>\nThe test is not valid unless the chromatogram obtained with solution (3) appears as a single compact spot.<\/p>\n

TESTS<\/h2>\n

Dissolution<\/h3>\nComplies with the requirements stated under Unlicensed Medicines, Oral Suspensions. Use a volume of the oral suspension containing one dose.<\/p>\n

SYSTEM SUITABILITY<\/h4>\nThe test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks due to nadolol and impurity D is at least 8.0.<\/p>\n

DETERMINATION OF CONTENT<\/h3>\nDetermine the weight per mL of the oral suspension, Appendix V G, and calculate the content of C17<\/sub>H27<\/sub>NO4<\/sub>, weight in volume, using the declared content of C17<\/sub>H27<\/sub>NO4<\/sub> in nadolol BPCRS.<\/p>\n

MOBILE PHASE<\/h3>\n
1 volume of 2M ammonium hydroxide, 1 volume of dichloromethane and 8 volumes of acetone.<\/p>\n

SYSTEM SUITABILITY<\/h3>\n
The test is not valid unless the chromatogram obtained with solution (3) appears as a single compact spot.<\/p>\n

Dissolution<\/h3>\n
Complies with the requirements stated under Unlicensed Medicines, Oral Suspensions. Use a volume of the oral suspension containing one dose.<\/p>\n

SYSTEM SUITABILITY<\/h4>\n
The test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks due to nadolol and impurity D is at least 8.0.<\/p>\n

DETERMINATION OF CONTENT<\/h3>\n
Determine the weight per mL of the oral suspension, Appendix V G, and calculate the content of C_{17<\/sub>H_{27<\/sub>NO_{4<\/sub>, weight in volume, using the declared content of C_{17<\/sub>H_{27<\/sub>NO_{4<\/sub> in nadolol BPCRS.<\/p>\n}}}}}}